<prompt> Secukinumab isAnti IL 1Anti IL 6Anti IL 17Anti IL 23  <response>: Ustekinumab anti-IL-1223 and secukinumab anti-IL-17 monoclonal antibodies have shown promising efficacy in clinical trials, but have not yet been approved for use in Ankylosing Spondylitis. Reference: Harrison;s Principles of Internal Medicine; kd tripathi 9th ed 